Metabolic syndrome and obsessive-compulsive disorder: A naturalistic Italian study

General Hospital Psychiatry

Volumn 35, Issue 2, 2013, Pages 154-159

  Albert, Umberto ^a   Aguglia, Andrea ^a   Chiarle, Alice ^a   Bogetto, Filippo ^a   Maina, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antipsychotic; Metabolic syndrome; Obesity; Obsessive compulsive disorder; Weight gain

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG THERAPY; DSM-IV-TR; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ITALY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III; OBESITY; OBSESSIVE COMPULSIVE DISORDER; PHYSICAL ACTIVITY; PREVALENCE; SEDENTARY LIFESTYLE; SMOKING; SOCIAL CLASS; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; ITALY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OBSESSIVE-COMPULSIVE DISORDER; SEXISM; WEIGHT GAIN;

EID: 84875366572     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.10.004     Document Type: Article

References (75)

1. Isomaa B., Almgren P., Tuomi T., Tuomi T., Taskinen M.R., Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
2. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
3. Resnick H.E., Jones K., Ruotolo G., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2003, 26(3):861-867.
4. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108(4):414-419.
5. Kurl S., Laukkanen J.A., Niskanen L., et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006, 37:806-811.
6. Khang Y.H., Cho S.I., Kim H.R. Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the metabolic syndrome using the new harmonised definition: findings from nationally representative longitudinal data from an Asian population. Atherosclerosis 2010, 213(2):579-585.
7. Gupta A.K., Prieto-Merino D., Dahlöf B., Sever P.S., Poulter N.R., ASCOT Investigators Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14.120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabet Med 2011, 28(8):941-947.
8. Joseph J., Svartberg J., Njølstad I., Schirmer H. Risk factors for type 2 diabetes in groups stratified according to metabolic syndrome: a 10-year follow-up of the Tromsø Study. Eur J Epidemiol 2011, 26(2):117-124.
9. Tanner R.M., Baber U., Carson A.P., et al. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol 2011, 108(2):227-232.
10. Novelletto B.F., Guzzinati S., Avogaro A. Prevalence of metabolic syndrome and its relationship with clinically prevalent cardiovascular disease in the Veneto region, northeastern Italy. Metab Syndr Relat Disord 2012, 10(1):56-62.
11. Ford E.S., Giles W.H., Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004, 27:2444-2449.
12. Balkau B., Vernay M., Mhamdi L., et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 2003, 29:526-532.
13. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004, 164:1066-1076. DECODE Study Group.
14. Miccoli R., Bianchi C., Odoguardi L., et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005, 15:250-254.
15. Perez Jimenez F., Mora Navarro G., Diez Espino J. Impacto del síndrome metabolico en la salud publica en España. Med Clin (Barc) 2006, 7:8-12.
16. McEvoy J.P., Meyer J.M., Goff D.C., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
17. McIntyre R.S., Danilewitz M., Liauw S.S., et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010, 126(3):366-387.
18. Fagiolini A., Frank E., Turkin S., Houck P.R., Soreca I., Kupfer D.J. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry 2008, 69:678-679.
19. Cardenas J., Frye M.A., Marusak S.L., et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008, 106:91-97.
20. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008, 10(7):788-797.
21. Fiedorowicz J.G., Palagummi N.M., Forman-Hoffman V.L., Miller D.D., Haynes W.G. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008, 20:131-137.
22. McIntyre R.S., Woldeyohannes H.O., Soczynska J.K., et al. The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. Adv Ther 2010, 27(11):828-836.
23. Garcia-Portilla M.P., Saiz P.A., Benabarre A., et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008, 106:197-201.
24. Sicras A., Rejas J., Navarro R., Serrat J., Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008, 10:607-616.
25. van Winkel R., De Hert M., Van Eyck D., et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008, 10:342-348.
26. Salvi V., Albert U., Chiarle A., Soreca I., Bogetto F., Maina G. Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry 2008, 30:318-323.
27. Yumru M., Savas H.A., Kurt E., et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007, 98:247-252.
28. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007, 89(1-3):91-100.
29. Guan N., Liu H., Diao F., Zhang J., Zhang M., Wu T. Prevalence of metabolic syndrome in bipolar patients initiating acute-phase treatment: a 6-month follow up. Psychiatry Clin Neurosci 2010, 64(6):625-633.
30. Salvi V., D'Ambrosio V., Rosso G., Bogetto F., Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci 2011, 65(1):47-54.
31. Carroll D., Phillips A.C., Thomas G.N., Gale C.R., Deary I., Batty G.D. Generalized anxiety disorder is associated with metabolic syndrome in the Vietnam experience study. Biol Psychiatry 2009, 66(1):91-93.
32. Jakovljević M., Babić D., Crncević Z., Martinac M., Maslov B., Topić R. Metabolic syndrome and depression in war veterans with post-traumatic stress disorder. Psychiatr Danub 2008, 20(3):406-410.
33. Heppner P.S., Crawford E.F., Haji1 U.A., et al. The association of posttraumatic stress disorder and metabolic syndrome: a study of increased health risk in veterans. BMC Med 2009, 7:1-8.
34. Weiss T., Skelton K., Phifer J., et al. Posttraumatic stress disorder is a risk factor for metabolic syndrome in an impoverished urban population. Gen Hosp Psychiatry 2011, 33:135-142.
35. Jin H., Lanouette N.M., Mudaliar S., et al. Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome. J Clin Psychopharmacol 2009, 29(3):210-215.
36. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006, 11:622-632.
37. Maina G., Pessina E., Albert U., Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment resistant-obsessive-compulsive disorder. Eur Neuropsychopharmacol 2008, 18:364-372.
38. Maher A.R., Maglione M., Bagley S., et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011, 306(12):1359-1369.
39. Matsunaga H., Nagata T., Hayashida K., Ohya K., Kiriike N., Stein D.J. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009, 70(6):863-868.
40. Maina G., Albert U., Salvi V., Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004, 65(10):1365-1371.
41. Goodman W.K., Price L.H., Rasmussen S.A., et al. The Yale-Brown Obsessive-Compulsive Scale: I. development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
42. Goodman W.K., Price L.H., Rasmussen S.A., et al. The Yale-Brown Obsessive-Compulsive Scale: II. validity. Arch Gen Psychiatry 1989, 46:1012-1016.
43. Bogetto F., Venturello S., Albert U., Maina G., Ravizza L. Gender-related clinical differences in obsessive-compulsive disorder. Eur Psychiatry 1999, 14(8):434-441.
44. Maina G., Albert U., Bogetto F., Vaschetto P., Ravizza L. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999, 89(1):49-58.
45. Albert U., Aguglia E., Maina G., Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002, 63(11):1004-1009.
46. D'Ambrosio V., Albert U., Bogetto F., Maina G. Obsessive-compulsive disorder and cyclothymic temperament: an exploration of clinical features. J Affect Disord 2010, 127(1-3):295-299.
47. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
48. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959, 32:50-55.
49. World Health Organization Obesity: preventing and managing the global epidemic: report of a WHO consultation on obesity 1997, World Health Organization, Geneva.
50. James W.P. The dietary challenge for the European Union. Public Health Nutr 2001, 4(2A):341-351.
51. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
52. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
53. Bo S., Ciccone G., Pearce N., et al. Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. Diabetes Res Clin Pract 2007, 75(3):362-365.
54. Bonora E., Kiechl S., Willeit J., et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck study. Int J Obes Relat Metab Disord 2003, 27(10):1283-1289.
55. Mancia G., Bombelli M., Corrao G., et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007, 49(1):40-47.
56. Drummond L.M., Boschen M.J., Cullimore J., Khan-Hameed A., White S., Ion R. Physical complications of severe, chronic obsessive-compulsive disorder: a comparison with general psychiatric inpatients. Gen Hosp Psychiatry 2012, [Epub ahead of print].
57. Moritz S., Rufer M., Fricke S., et al. Quality of life in obsessive-compulsive disorder before and after treatment. Compr Psychiatry 2005, 46:453-459.
58. Albert U., Maina G., Bogetto F., Chiarle A., Mataix-Cols D. Clinical predictors of health-related quality of life in obsessive-compulsive disorder. Compr Psychiatry 2010, 51:192-200.
59. Fontenelle I.S., Fontenelle L.F., Borges M.C., et al. Quality of life and symptom dimensions of patients with obsessive-compulsive disorder. Psychiatry Res 2010, 179:198-203.
60. Hou S.Y., Yen C.F., Huang M.F., Wang P.W., Yeh Y.C. Quality of life and its correlates in patients with obsessive-compulsive disorder. Kaohsiung J Med Sci 2010, 26:397-407.
61. Timpano K.R., Rubenstein L.M., Murphy D.L. Phenomenological features and clinical impact of affective disorders in OCD: a focus on the bipolar disorder and OCD connection. Depress Anxiety 2012, 29(3):226-233.
62. Facchini F.S., Hollenbeck C.B., Jeppesen J., Chen Y.D., Reaven G.M. Insulin resistance and cigarettes smoking. Lancet 1992, 339:1128-1130.
63. Attvall S., Fowelin J., Lager I., Von Schenck H., Smith U. Smoking induces insulin resistance: a potential link with the insulin resistance syndrome. J Intern Med 1993, 233:327-332.
64. Tahtinen T.M., Vanhala M.J., Oikarinen J.A., Keinanen-Kiukaaniemi S.M. Effect of smoking on the prevalence of insulin resistance-associated cardiovascular risk factor among Finnish men in military service. J Cardiovasc Risk 1998, 5:319-323.
65. Ambrose J.A., Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004, 43:1731-1737.
66. Park H.S., Oh S.W., Cho S.I., Choi W.H., Kim Y.S. The metabolic syndrome and associated lifestyle factors among South Korean adults. Int J Epidemiol 2004, 33:328-336.
67. Miyatake N., Wada J., Kawasaki Y., Nishii K., Makino H., Numata T. Relationship between metabolic syndrome and cigarette smoking in Japanese population. Intern Med 2006, 45:1039-1043.
68. Tonstad S., Andrew Johnson J. Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil 2006, 13:507-514.
69. Achten J., Jeukendrup A.E. Optimizing fat oxidation through exercise and diet. Nutrition 2004, 20(7-8):716-727.
70. Solomon T.P., Sistrun S.N., Krishnan R.K., et al. Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults. J Appl Physiol 2008, 104(5):1313-1319.
71. Eckel R.H., Alberti K.G., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2010, 375(9710):181-183.
72. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56(14):1113-1132.
73. Maina G., Albert U., Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001, 16:33-38.
74. Ruscio A.M., Stein D.J., Chiu W.T., et al. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010, 15(1):53-63.
75. Ng F., Mammen O.K., Wilting I., et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009, 11(6):559-595.